Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

ArcherDX, Inc C.RCHR


Primary Symbol: RCHR

Healthcare Biotechnology
ArcherDX, Inc. is a genomics company. The Company’s product development platform, with its anchored multiplex polymerase chain reaction (AMP), enables to develop products and services that allow for therapy optimization and cancer monitoring. The Company offers research use only (RUO) products, in-vitro diagnostic (IVD) products and services for clinical applications. Its RUO product lines consist of deoxyribonucleic acid (DNA)-based VariantPlex, ribonucleic acid (RNA)-based FusionPlex, circulating tumor DNA (ctDNA)-based LiquidPlex and RNA-based Immunoverse, and personalized cancer monitoring (PCM). The Company's offerings include commercial RUO products and services that laboratories use to conduct genomic analysis for therapy optimization and cancer monitoring. The Company’s modular product development platform combines its AMP chemistry, target-specific primers, ancillary reagents, and bioinformatics software to detect mutations.


NDAQ:RCHR - Post by User

ArcherDX, Inc
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(655)
•••
Post by TimeBuilderon Nov 28, 2022 2:45pm
186 Views
Post# 35134604

Archer Trading NR

Archer Trading NR

Archer Exploration to Resume Trading on the Canadian Securities Exchange

Newswire.ca - Mon Nov 28, 10:45AM CST
 

VANCOUVER, BC, Nov. 28, 2022 /CNW/ - Archer Exploration Corp. (CSE: RCHR) (the "Company" or "Archer") is pleased to announce that, as set out in the bulletin of the Canadian Securities Exchange (the "CSE") on November 28, 2022, its common shares will resume trading on Tuesday, November 29, 2022.

Read more at newswire.ca

Provided Content: Content provided by Newswire.ca. The Globe and Mail was not involved, and material was not reviewed prior to publication.


<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities